Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Population genomics analysis on public genomic datasets (EAS vs EUR), compared allele frequencies for major pharmacogenes, evolutionary forces explaining PGx variant frequency differences

A systematic population genomics analysis compares pharmacogenomic variation between East Asian (EAS) and European (EUR) populations using public genomic datasets. EAS populations generally harbor lower frequencies of pharmacogenomic variants previously associated with reduced drug response compared to EUR populations. Transport genes such as SLCO1B1/SLCO1B7 show particularly marked differentiation. Evolutionary forces (drift, natural selection) explain a significant part of these differences. These findings have direct implications for adapting PGx panels to non-European populations.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

PGx panels currently deployed in routine clinical practice are largely optimized for European populations. This population genomics study demonstrates that variants and their frequencies differ significantly in Asian populations, arguing for population-specific PGx panels — yet another argument favoring exhaustive pharmacogene sequencing over panels targeting EU-centric variants.

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 2/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 8/10